

# Myeloma Service– Trial guide

	Smouldering MM	Renal Impairment	Transplant eligible	Transplant ineligible	Amyloid
Newly Diagnosed	DEFENCE trial Denosumab vs placebo	<b>OPTIMAL</b> eGFR < 30ml/min Bendamustin/dex + Thalidomide vs Bortezomib	<b>CARDAMON</b> CCD induction, foll by ASCT vs CFZ Maintenance  <b>MUK 9</b> High risk Myeloma		
Relapsed	1 <sup>st</sup> relapse: MM XII – ITD reinduction followed by second ASCT				<b>Tourmaline</b> (Oral proteasome inhibitor) Ixa/Dex vs Len/ Dex. For PI naive patients
	<b>MUK8</b> Ixazomib/ Cyclo/ Dex vs Cyclo/ Dex (Len and Velcade exposed patients)		<b>C16029</b>  Pom/Dex vs High dose Ixazomib/ Dex (Len refractory and PI exposed)		
Relapsed/ Refractory MM	<b>C92480 + Dex trial</b>  Lenalidomide, Pomalidomide and Velcade exposed patients		<b>BET inhibitor +/- combination with Daratumumab</b> Lenalidomide and Velcade exposed	<b>BCMA ADC</b> single agent – post Dara patients	

**OPEN**    **COMING SOON**    **EPH = Early Phase Hub**